Waters Corp (WAT.N) raised the decrease finish of its full-year revenue forecast on Monday, following stronger-than-expected second-quarter outcomes fueled by rising demand from biotech corporations for its laboratory instruments utilized in drug improvement and analysis.
The firm, which earns most of its income from biopharmaceutical purchasers, now expects adjusted earnings per share (EPS) for 2025 to vary between $12.95 and $13.05, up from its earlier vary of $12.75 to $13.05.
CEO Udit Batra attributed the improved outlook to “strong execution against our commercial growth initiatives, rapid uptake of our new products, and contribution from incremental growth vectors such as GLP-1s, PFAS, and generics.”
Waters lately introduced a deal to amass a bioscience and diagnostics unit spun off from Becton Dickinson (BDX.N), aiming to broaden its footprint in scientific and diagnostic purposes. Batra mentioned the acquisition would assist the corporate faucet into extra resilient, high-volume markets.
For the third quarter, Waters initiatives adjusted EPS of $3.15 to $3.25, aligning intently with the analyst consensus of $3.23, in keeping with LSEG information.
In Q2, Waters posted adjusted EPS of $2.95, barely above analyst expectations of $2.94, whereas income rose 9% year-over-year to $771.3 million, surpassing the estimated $748.7 million.
The firm’s efficiency follows an analogous development set by its bigger peer Thermo Fisher Scientific (TMO.N), which additionally raised its revenue steerage final month amid sturdy demand for its drug improvement merchandise.
